`U.S. Patent 10,335,462
`UNITED STATES PATENT AND TRADEMARK OFFICE
`______________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`______________________
`
`MYLAN PHARMACEUTICALS INC.,
`Petitioner
`
`v.
`NOVO NORDISK A/S,
`Patent Owner
`______________________
`Case IPR2023-00724
`Patent 10,335,462
`______________________
`
`DECLARATION OF ANNE FLINT PH.D.
`
`PROTECTIVE ORDER MATERIAL
`
`Novo Nordisk Exhibit 2051
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00001
`
`
`
`IPR2023-00724
`U.S. Patent 10,335,462
`I, Anne Flint, hereby declare under penalty of perjury:
`
`1. My name is Anne Flint. I am a citizen of Denmark, and I reside in
`
`Copenhagen, Denmark.
`
`2.
`
`I am a clinical development scientist. I earned my MSc in Human
`
`Physiology and Ph.D. in Human Nutrition at the University of Copenhagen, in 1993
`
`and 1999, respectively. After that, I was employed at the University of Copenhagen
`
`as assistant and associate professor until May 2005, where I started in Novo Nordisk.
`
`I am currently a Senior Clinical Pharmacology Scientific Director at Novo Nordisk.
`
`
`
`2
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`PROTECTIVE ORDER MATERIAL
`
`Novo Nordisk Exhibit 2051
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00002
`
`
`
`IPR2023-00724
`U.S. Patent 10,335,462
`
`' All subsequent exhibits cited herein have a single sheet appended before the start
`
`of the cited documents, whichI understand identifies the underlying metadata of
`
`eachcited document. My statements that I recognize the documentsas true and
`
`correct copies, or that the documents were madeand kept in the ordinary course of
`
`business, apply to the documents themselves, not the appended metadata readout.
`
`PROTECTIVE ORDER MATERIAL
`
`Novo Nordisk Exhibit 2051
`Mylan Pharms.Inc. v. Novo Nordisk A/S
`IPR2023-00724
`
`Page 00003
`
`
`
`IPR2023-00724
`U.S. Patent 10,335,462
`
`PROTECTIVE ORDER MATERIAL
`
`NovoNordisk Exhibit 2051
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`
`Page 00004
`
`
`
`IPR2023-00724
`U.S. Patent 10,335,462
`
`PROTECTIVE ORDER MATERIAL
`
`NovoNordisk Exhibit 2051
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`
`Page 00005
`
`
`
`IPR2023-00724
`U.S. Patent 10,335,462
`
`PROTECTIVE ORDER MATERIAL
`
`NovoNordisk Exhibit 2051
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`
`Page 00006
`
`
`
`—= S N ~ ° S — SS =
`Ys,
`qG N O 2 =O@= — oS U2 U2 n i OV m
`
`;;
`
`PROTECTIVE ORDER MATERIAL
`
`NovoNordisk Exhibit 2051
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`
`Page 00007
`
`
`
`—= S N ~ ° S — SS =
`Ys,
`ae) 2 —oO—= — oO oe) 2 “Nn = ON N
`
`C NM
`
`PROTECTIVE ORDER MATERIAL
`
`NovoNordisk Exhibit 2051
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`
`Page 00008
`
`
`
`IPR2023-00724
`U.S. Patent 10,335,462
`
`PROTECTIVE ORDER MATERIAL
`
`NovoNordisk Exhibit 2051
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`
`Page 00009
`
`
`
`—_ N
`
`IPR2023-00724
`U.S. Patent 10,335,462
`
`PROTECTIVE ORDER MATERIAL
`
`— o
`
`NovoNordisk Exhibit 2051
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`
`Page 00010
`
`
`
`IPR2023-00724
`U.S. Patent 10,335,462
`
`
`
`
`
`
`***
`
`I have been warned that willful false statements and the like are punishable by fine
`
`or imprisonment, or both (18 U.S.C. 1001) and may jeopardize the validity of the
`
`patent at issue in this proceeding, I declare under penalty of perjury under the laws
`
`of the United States of America that the foregoing is true and correct.
`
`
`
`Executed on January 17, 2024 at Copenhagen, Denmark.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`/Anne Flint /
`
`Anne Flint, Ph.D.
`
`11
`
`PROTECTIVE ORDER MATERIAL
`
`Novo Nordisk Exhibit 2051
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00011
`
`